ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 232 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2022. The put-call ratio across all filers is 0.85 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,703,073 | +113287.0% | 36,919 | -1.5% | 0.02% | -13.0% |
| Q1 2023 | $1,502 | -99.9% | 37,467 | +4.9% | 0.02% | -28.1% |
| Q3 2022 | $1,480,000 | +51.3% | 35,729 | +118.0% | 0.03% | +23.1% |
| Q2 2022 | $978,000 | +162.2% | 16,391 | +270.0% | 0.03% | +333.3% |
| Q4 2021 | $373,000 | -88.4% | 4,430 | -87.6% | 0.01% | -88.5% |
| Q3 2021 | $3,228,000 | +113.5% | 35,789 | +125.7% | 0.05% | +79.3% |
| Q2 2021 | $1,512,000 | -38.3% | 15,857 | -10.5% | 0.03% | -58.0% |
| Q4 2020 | $2,452,000 | +86.6% | 17,712 | +10.8% | 0.07% | +21.1% |
| Q3 2020 | $1,314,000 | +57.6% | 15,985 | +49.9% | 0.06% | +39.0% |
| Q2 2020 | $834,000 | +37.2% | 10,667 | -25.0% | 0.04% | +95.2% |
| Q3 2019 | $608,000 | +41.4% | 14,214 | +124.1% | 0.02% | +61.5% |
| Q1 2017 | $430,000 | +83.0% | 6,343 | +159.9% | 0.01% | +62.5% |
| Q3 2015 | $235,000 | – | 2,441 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |